Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × birtamimab × Plasma cell × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 150 Bortezomib 86 Lenalidomide 82 Melphalan 43 Thalidomide 39 daratumumab 38 Cyclophosphamide 33 pomalidomide 32 Calcium Dobesilate 26 carfilzomib 23 Prednisone 18 Filgrastim 13 Doxorubicin 13 elotuzumab 11 ixazomib 10 Peripheral Blood Stem Cell Transplantation 10 isatuximab 9 dexamethasone acetate 9 Vincristine 9 Granulocyte Colony-Stimulating Factor 9 belantamab mafodotin 8 Zoledronic Acid 8 Epoetin Alfa 7 selinexor 5 fludarabine 5 dexamethasone 21-phosphate 5 auricularum 5 Carmustine 5 Stem Cell Transplantation 4 Radiotherapy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02312206 2023-11-14

VITAL

Prothena Biosciences Ltd.

Phase 3 Terminated

260 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡